Chengping Hu
Central South University(CN)Anhui Provincial Hospital(CN)Second Xiangya Hospital of Central South University(CN)Detection Limit (United States)(US)Xiangya Hospital Central South University(CN)Gas Technology Institute(US)Dali University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Asthma and respiratory diseases, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study(2011)4,075 cited
- → Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial(2014)1,963 cited
- → Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)(2015)464 cited
- → Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial(2022)372 cited
- → Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial(2019)351 cited